2024年11月29日 · In this Review, we describe the current first-line treatment options for EGFR -mutant NSCLC, provide an overview of the mechanisms of acquired resistance to third-generation EGFR TKIs and explore...

2025年3月12日 · 1 目前针对egfr罕见突变的治疗选择有限，且耐药问题突出。. 2 第三代tki（如奥希替尼、阿美替尼、贝福替尼等）的出现为 egfr 罕见突变治疗带来了新的希望。. 1 赛美纳的研发充分考虑了 egfr 罕见突变的异质性，能够根据不同的突变类型提供精准的治疗方案。. 编者按：近年来，非小细胞肺癌（nsclc ...

2024年11月8日 · 以新一代alk-tki为代表的靶向治疗，显著改善alk阳性nsclc的生存，成为alk阳性晚期nsclc患者的治疗首选。 2024版诊疗指南优先推荐 阿来替尼 、 布格替尼 、 洛拉替尼 等第二代ALK抑制剂作为Ⅳ期ALK融合NSCLC患者的一线治疗。

2024年12月10日 · EGFR 突变与 EGFR 酪氨酸激酶抑制剂（TKI）疗效相关性的发现彻底改变了非小细胞肺癌（NSCLC）患者的治疗范式。 目前，第三代 EGFR TKI 通常能够有效穿透血脑屏障，是晚期 EGFR 突变 NSCLC 的标准一线治疗。 正在研究第三代 EGFR TKI 与抗血管生成药物、化疗、EGFR-MET 双特异性抗体埃万妥单抗或局部肿瘤消融的合理组合，作为延迟耐药性和增加临床获益的策略。 此外，EGFR TKI 正在早期或局部晚期 EGFR 突变 NSCLC 患者中进行评 …

2025年3月15日 · Lung cancer is the leading cause of cancer-related mortality worldwide [].Approximately 85% of lung cancers are non-small cell lung cancer (NSCLC) [].EGFR tyrosine kinase inhibitors (EGFR-TKIs) reportedly improve outcomes in patients with advanced EGFR-mutant NSCLC [3,4,5,6].However, despite the initial remarkable response, patients inevitably develop acquired drug resistance to EGFR-TKI ...

4 天之前 · (ClinicalTrials.gov Identifier: NCT03866499) to compare the efficacy and safety of rezivertinib, a third-generation tyrosine kinase inhibitor (TKI), with gefitinib, a first-generation TKI, as first-line therapies in EGFR-mutated locally advanced or metastatic NSCLC. Progression-free survival was the primary endpoint.

2025年3月13日 · Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer and is typically linked to a poor prognosis [].At initial diagnosis, 46.8–61.2% of NSCLC patients identified as having stage IV disease [].Stage IV NSCLC is generally considered incurable, with palliative care serving as the cornerstone of management [].However, advancements in precision medicine for advanced NSCLC ...

2024年11月1日 · Third-generation EGFR tyrosine kinase inhibitor (TKIs) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations, with improved long-term outcomes compared to first-generation TKIs. Nevertheless, disease progression inevitably occurs, limiting osimertinib long-term efficacy.

2025年3月2日 · MET是EGFR TKI获得性耐药的生物标志物。三期SAFFRON试验正在先前经osimertinib治疗的EGFR突变和MET过表达的转移性NSCLC患者中，评估MET抑制剂savolitinib联合osimertinib治疗中的效果。Telisotuzumab vedotin是一种抗MET ADC，目前正处于III期临床开发阶段，用于先前治疗过的MET过表达 ...

2024年11月27日 · 随着精准医学的不断发展，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）推动了晚期 非小细胞肺癌 （NSCLC）的治疗变革，其在围术期领域的探索成为目前发展的重要方向之一。 目前，EGFR-TKI为早期EGFR突变NSCLC的术后辅助靶向治疗带来了革新。 基于此，医脉通特邀 内蒙古医科大学附属医院王宇飞教授 解读EGFR突变早期NSCLC的围术期治疗进展，展望EGFR-TKI在该领域的治疗前景与临床挑战。 EGFR-TKI开启EGFR突变NSCLC术后 …

After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations.

2024年5月21日 · 其中，《中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2024》（下称《CSCO NSCLC指南2024》）的更新受到了各界高度关注，表皮生长因子受体（EGFR）阳性晚期非小细胞肺癌（NSCLC）靶向治疗更是肺癌临床工作者所关注的焦点，近年来EGFR阳性晚期NSCLC临床诊疗现状如何？ 有哪些重磅突破进展？ 2024 CSCO指南有何最新推荐？ 医脉通特邀 中国医学科学院肿瘤医院王洁教授 对此进行深析、分享。 2003年，美国食品药品监督管理 …

一代/二代EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）用于 EGFR 经典突变（EGFR 外显子19缺失突变或外显子21 L858R点突变）晚期NSCLC患者的一线治疗，可使患者的中位无进展生存期（progression-free survival, PFS）提升至9.2个月-14.7个月 [5 - 13]，显著优于化疗，但不可避免地出现疾病进展，其中以继发性 EGFR T790M突变最为常见 [14]。

4 天之前 · In the MARIPOSA study, a combination of amivantamab, which is an MET bispecific antibody with immune cell–directing activity, was combined with a third-generation EGFR TKI, lazertinib, and advanced as a first-line treatment for common EGFR mutation–positive advanced non–small cell lung cancer patients vs osimertinib. In this trial, 1074 ...

1 天前 · Non-small cell lung cancer (NSCLC) is the most common type, with lung adenocarcinoma (LUAD) being the most prevalent histological subtype, ... In the EGFR-TKI treatment test, 3 out of 10 patients with only extrapulmonary progression were not correctly reported (Table 3). The actual PFS for Case 9 was 39.2 months, while the predicted probability ...

2 天之前 · Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This study assesses its efficacy in advanced NSCLC harboring various EGFR exon 19 mutations. Conducted as a retrospective, two-center analysis, the study includes patients with advanced NSCLC and exon 19 mutations who received osimertinib. A total of 272 patients were analyzed for survival ...

2025年3月14日 · Zheng, Q. et al. NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multicenter study in China. Lung Cancer 194 , 107897 ...

2025年3月6日 · Repotrectinib has FDA approval for ROS1-altered NSCLC. It has an ORR of 79% in TKI-naive patients and 38% in patients ... P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C ...

TKIs are increasingly accepted by clinicians as induction therapy in NSCLC. Many studies have demonstrated that neoadjuvant therapy increases the likelihood of surgery and is associated with good resection rates, as evidenced by high prospective downstaging rates in patients with locally advanced NSCLC.

2024年5月1日 · This finding dramatically changed the landscape of neoadjuvant treatment of NSCLC and provided the foundation for exploration of a variety of neoadjuvant treatment possibilities including targeted therapy and therefore epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) preoperative treatment for EGFR-mutated NSCLC [4] as ...